Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.45 |
| ▸ | KDR | P35968 | 6/20 | 0.42 |
| ▸ | TEK | Q02763 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BLK | P51451 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996933 | 0.90 | LCK (0.58) | LCKMAPK14KDRBTKSRC | |
| SCHEMBL5999306 | 0.85 | LCK (0.42) | LCKMAPK14KDRTEKJAK3 | |
| SCHEMBL5997079 | 0.81 | LCK (0.44) | LCKMAPK14KDRTEKBLK | |
| SCHEMBL2495023 | 0.80 | BTK (0.69) | LCKMAPK14KDRTEKJAK3 | |
| SCHEMBL5996066 | 0.79 | LCK (0.45) | LCKMAPK14KDRBLKBTK | |
| SCHEMBL5998218 | 0.79 | BTK (0.39) | LCKMAPK14KDRTEKJAK3 | |
| SCHEMBL5994786 | 0.79 | HSD11B1 (0.40) | LCKMAPK14KDRBLKBTK | |
| SCHEMBL5997421 | 0.79 | SRC (0.57) | LCKMAPK14JAK3ABL1SRC | |
| SCHEMBL5995525 | 0.77 | LCK (0.43) | LCKMAPK14KDRBLKBTK | |
| SCHEMBL2499026 | 0.76 | BTK (0.62) | LCKMAPK14KDRTEKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | LCK 4/4885MAPK14 401/4885KDR 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.